Emcure Pharmaceuticals (India) Performance
| EMCURE Stock | 1,421 33.45 2.41% |
The firm shows a Beta (market volatility) of 0.7, which means possible diversification benefits within a given portfolio. As returns on the market increase, Emcure Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Emcure Pharmaceuticals is expected to be smaller as well. Emcure Pharmaceuticals right now shows a risk of 2.25%. Please confirm Emcure Pharmaceuticals skewness, and the relationship between the total risk alpha and day median price , to decide if Emcure Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Emcure Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Emcure Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Emcure Pharma share surge 6 percent after healthy Q2 earnings show - Moneycontrol | 11/08/2024 |
Emcure |
Emcure Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 143,220 in Emcure Pharmaceuticals on September 26, 2024 and sell it today you would lose (1,150) from holding Emcure Pharmaceuticals or give up 0.8% of portfolio value over 90 days. Emcure Pharmaceuticals is generating 0.0121% of daily returns and assumes 2.2479% volatility on return distribution over the 90 days horizon. Simply put, 20% of stocks are less volatile than Emcure, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Emcure Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Emcure Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Emcure Pharmaceuticals, and traders can use it to determine the average amount a Emcure Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0054
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EMCURE |
Estimated Market Risk
| 2.25 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Emcure Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Emcure Pharmaceuticals by adding Emcure Pharmaceuticals to a well-diversified portfolio.
Emcure Pharmaceuticals Fundamentals Growth
Emcure Stock prices reflect investors' perceptions of the future prospects and financial health of Emcure Pharmaceuticals, and Emcure Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Emcure Stock performance.
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 295.8 B | ||||
| Price To Book | 9.39 X | ||||
| Price To Sales | 3.92 X | ||||
| Revenue | 69.17 B | ||||
| EBITDA | 12.05 B | ||||
| Book Value Per Share | 162.97 X | ||||
| Earnings Per Share | 26.38 X | ||||
About Emcure Pharmaceuticals Performance
By analyzing Emcure Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Emcure Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Emcure Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Emcure Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Emcure Pharmaceuticals is entity of India. It is traded as Stock on NSE exchange.Things to note about Emcure Pharmaceuticals performance evaluation
Checking the ongoing alerts about Emcure Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Emcure Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 87.0% of the company shares are held by company insiders |
- Analyzing Emcure Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Emcure Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Emcure Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Emcure Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Emcure Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Emcure Pharmaceuticals' stock. These opinions can provide insight into Emcure Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Emcure Stock analysis
When running Emcure Pharmaceuticals' price analysis, check to measure Emcure Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emcure Pharmaceuticals is operating at the current time. Most of Emcure Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Emcure Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emcure Pharmaceuticals' price. Additionally, you may evaluate how the addition of Emcure Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |